Skip to content

Study · Observational study · 2009

6 results

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.

Bodri D, Guillén JJ, Galindo A, Mataró D, Pujol A, Coll O

Fertility and sterility25 Mar 2008Cited by 76 (Europe PMC)

PMID18367175 (opens in a new tab)DOI10.1016/j.fertnstert.2007.11.049 (opens in a new tab)PepBankPUB-18367175
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In egg donors, triptorelin triggering was linked to a mature oocyte proportion comparable to recombinant hCG.

    In plain wordsIn egg donors, triptorelin triggering was linked to a mature oocyte proportion comparable to recombinant hCG.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeMature oocyte proportion
    Study

    n: not reported in source

    Comparator
    Recombinant hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.2 mgAs given in this study (human).

    Source sentences

    Summary
    The proportion of mature oocytes was comparable, whereas the difference in the fertilization rate reached statistical significance (65% vs. 69%).
    2 context sentences
    Summary · context
    Retrospective, cohort study.
    Summary · context
    Controlled ovarian hyperstimulation of egg donors with GnRH antagonist protocol triggered with recombinant hCG (rhCG; 250 microg) or GnRH agonist (triptorelin 0.2 mg) based on the physician's decision.
  2. 02HumanObservational studyEfficacy outcome

    In egg donors, fertilization rate differed significantly between triptorelin-triggered and recombinant hCG-triggered cycles (65% vs. 69%). The abstract does not label which value belongs to which group.

    In plain wordsIn egg donors, fertilization rate differed between triptorelin and hCG triggering (65% versus 69%).

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Direction not reportedFertilization rate
    Study

    n: not reported in source

    Comparator
    Recombinant hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.2 mgAs given in this study (human).

    Measurements

    Fertilization rate
    65%
    first value in '65% vs. 69%'
    Fertilization rate
    69%
    second value in '65% vs. 69%'

    Source sentences

    Summary
    The proportion of mature oocytes was comparable, whereas the difference in the fertilization rate reached statistical significance (65% vs. 69%).
    2 context sentences
    Summary · context
    Retrospective, cohort study.
    Summary · context
    Controlled ovarian hyperstimulation of egg donors with GnRH antagonist protocol triggered with recombinant hCG (rhCG; 250 microg) or GnRH agonist (triptorelin 0.2 mg) based on the physician's decision.
  3. 03HumanObservational studyEfficacy outcome

    In recipients, implantation rates did not differ significantly between triptorelin and recombinant hCG donor triggering.

    In plain wordsIn recipients, implantation rates did not differ significantly between triptorelin and recombinant hCG donor triggering.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeImplantation rate
    Study

    n: not reported in source

    Comparator
    Recombinant hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.2 mgAs given in this study (human).

    Source sentences

    Summary
    No significant differences were observed in the implantation rate or clinical and ongoing pregnancy rates per ET.
    2 context sentences
    Summary · context
    Retrospective, cohort study.
    Summary · context
    Controlled ovarian hyperstimulation of egg donors with GnRH antagonist protocol triggered with recombinant hCG (rhCG; 250 microg) or GnRH agonist (triptorelin 0.2 mg) based on the physician's decision.
  4. 04HumanObservational studyEfficacy outcome

    In recipients, clinical pregnancy rates did not differ significantly between triptorelin and recombinant hCG donor triggering.

    In plain wordsIn recipients, clinical pregnancy rates did not differ significantly between triptorelin and recombinant hCG donor triggering.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeClinical pregnancy rate
    Study

    n: not reported in source

    Comparator
    Recombinant hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.2 mgAs given in this study (human).

    Source sentences

    Summary
    No significant differences were observed in the implantation rate or clinical and ongoing pregnancy rates per ET.
    2 context sentences
    Summary · context
    Retrospective, cohort study.
    Summary · context
    Controlled ovarian hyperstimulation of egg donors with GnRH antagonist protocol triggered with recombinant hCG (rhCG; 250 microg) or GnRH agonist (triptorelin 0.2 mg) based on the physician's decision.
  5. 05HumanObservational studyEfficacy outcome

    In recipients, ongoing pregnancy rates did not differ significantly between triptorelin and recombinant hCG donor triggering.

    In plain wordsIn recipients, ongoing pregnancy rates did not differ significantly between triptorelin and recombinant hCG donor triggering.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeOngoing pregnancy rate
    Study

    n: not reported in source

    Comparator
    Recombinant hCG
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.2 mgAs given in this study (human).

    Source sentences

    Summary
    No significant differences were observed in the implantation rate or clinical and ongoing pregnancy rates per ET.
    2 context sentences
    Summary · context
    Retrospective, cohort study.
    Summary · context
    Controlled ovarian hyperstimulation of egg donors with GnRH antagonist protocol triggered with recombinant hCG (rhCG; 250 microg) or GnRH agonist (triptorelin 0.2 mg) based on the physician's decision.
  6. 06HumanObservational studySafety outcome

    In egg donors, triptorelin triggering was linked to less moderate or severe OHSS than recombinant hCG, with rates of 0% versus 1.26%.

    In plain wordsIn egg donors, triptorelin triggering was linked to less moderate or severe OHSS than recombinant hCG.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseModerate or severe OHSS
    Study

    n: not reported in source

    Comparator
    Recombinant hCG
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    0.2 mgAs given in this study (human).

    Measurements

    Moderate/severe OHSS incidence
    0%
    triptorelin (GnRH agonist) group
    Moderate/severe OHSS incidence
    1.26%
    recombinant hCG group

    Source sentences

    Summary
    The incidence of moderate/severe OHSS was 1.26% (13/1031; 95% confidence interval [CI], 0.74-2.15) and 0% (0/1046; 95% CI, 0.00-0.37) in the rhCG and GnRH agonist groups, respectively.
    2 context sentences
    Summary · context
    Retrospective, cohort study.
    Summary · context
    Controlled ovarian hyperstimulation of egg donors with GnRH antagonist protocol triggered with recombinant hCG (rhCG; 250 microg) or GnRH agonist (triptorelin 0.2 mg) based on the physician's decision.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.